Ferronova is an Adelaide-headquartered medical device company, bringing together patented magnetic probe technology from University of South Australia and magnetic nanoparticle technology from Victoria University of Wellington.
Current cancer staging technology uses gamma probes with radioactive tracers; these have significant logistical issues and, due to their low resolution, are not suitable for more complex cancers.
The Ferronova magnetic probe and tracer system is being developed to allow staging of complex cancers, initially targeting oral cavity and other head and neck cancers. Improved staging of these complex cancers is anticipated to allow better treatment, lower patient morbidity and reduced healthcare system costs.
Pre-clinical studies are commencing in Q2 2017, with pilot human trials expected by the start of 2018.